Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 14/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 14/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2020458 | 0.87 | SLC6A4 (0.36) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2020646 | 0.83 | GRM2 (0.43) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2024501 | 0.80 | SLC6A2 (0.46) | PARP1SLC6A4SLC6A2SLC6A3DRD2 | |
| SCHEMBL1002132 | 0.78 | PARP1 (0.39) | PARP1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1001900 | 0.77 | PARP1 (0.38) | PARP1SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL2025786 | 0.74 | SLC6A4 (0.36) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1003211 | 0.74 | PARP1 (0.41) | PARP1SLC6A2SLC6A3 | |
| SCHEMBL1005065 | 0.74 | PARP1 (0.37) | PARP1 | |
| SCHEMBL2023783 | 0.74 | GRM2 (0.51) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL5243321 | 0.73 | PARP1 (0.39) | PARP1DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | claimed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| EP-1778634-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | AstraZeneca AB (SE) | 2007-05-02 | — | — | EP | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | PARP1 3945/4885SLC6A4 465/4885SLC6A2 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.